These observations provide a rationale for selecting novel combination treatments that overcome nuclear EGFR-mediated therapeutic resistance, but these mechanisms need to be documented in cervical cancer biopsies and tested in preclinical xenograft studies. This evidence concerns the gene EGFR and cervical cancer.